Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions
The sphingosine 1-phosphate (S1P) signalling pathways have important and diverse functions. S1P receptors (S1PRs) have been proposed as a therapeutic target for various diseases due to their involvement in regulation of lymphocyte trafficking, brain and cardiac function, vascular permeability, and v...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 2021-09, Vol.398 (10306), p.1184-1194 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1194 |
|---|---|
| container_issue | 10306 |
| container_start_page | 1184 |
| container_title | The Lancet (British edition) |
| container_volume | 398 |
| creator | McGinley, Marisa P Cohen, Jeffrey A |
| description | The sphingosine 1-phosphate (S1P) signalling pathways have important and diverse functions. S1P receptors (S1PRs) have been proposed as a therapeutic target for various diseases due to their involvement in regulation of lymphocyte trafficking, brain and cardiac function, vascular permeability, and vascular and bronchial tone. S1PR modulators were first developed to prevent rejection by the immune system following renal transplantation, but the only currently approved indication is multiple sclerosis. The primary mechanism of action of S1PR modulators in multiple sclerosis is through binding S1PR subtype 1 on lymphocytes resulting in internalisation of the receptor and loss of responsiveness to the S1P gradient that drives lymphocyte egress from lymph nodes. The reduction in circulating lymphocytes presumably limits inflammatory cell migration into the CNS. Four S1PR modulators (fingolimod, siponimod, ozanimod, and ponesimod) have regulatory approval for multiple sclerosis. Preclinical evidence and ongoing and completed clinical trials support development of S1PR modulators for other therapeutic indications. |
| doi_str_mv | 10.1016/S0140-6736(21)00244-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2545986821</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673621002440</els_id><sourcerecordid>2545986821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-abf38b0c4517c24430848577824beb012ba0f19acd861049eb20a66a4ef669b83</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhi3UChbKT6Cy1As9pIwd2_GeKoRaioTEAai4WY4zYY0SO7WTSv339bKUQy-cZg7POx8PIScMvjBg6uwWmIBKNbU65ewzABeigj2yYqIRlRTNwzuyekUOyGHOTwAgFMh9clAL1kjgsCI_b6eND48x-4CUVdMm5mljZ6QJHU5zTHSM3TLY0mXqAx2XYfbTgDS7AVOJZWpDR-O8wURdDJ2ffQz5A3nf2yHj8Us9Ivffv91d_Kiuby6vLs6vKycZmyvb9rVuwQnJGlc-qEELLZtGc9FiC4y3Fnq2tq7TioFYY8vBKmUF9kqtW10fkdPd3CnFXwvm2Yw-OxwGGzAu2XAp5ForzVlBP_2HPsUlhXJdoRqpi0G5peSOcuW5nLA3U_KjTX8MA7MVb57Fm61Vw5l5Fm-g5D6-TF_aEbvX1D_TBfi6A7Do-O0xmew8BoedL6pn00X_xoq_KKeSEw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2575802451</pqid></control><display><type>article</type><title>Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>McGinley, Marisa P ; Cohen, Jeffrey A</creator><creatorcontrib>McGinley, Marisa P ; Cohen, Jeffrey A</creatorcontrib><description>The sphingosine 1-phosphate (S1P) signalling pathways have important and diverse functions. S1P receptors (S1PRs) have been proposed as a therapeutic target for various diseases due to their involvement in regulation of lymphocyte trafficking, brain and cardiac function, vascular permeability, and vascular and bronchial tone. S1PR modulators were first developed to prevent rejection by the immune system following renal transplantation, but the only currently approved indication is multiple sclerosis. The primary mechanism of action of S1PR modulators in multiple sclerosis is through binding S1PR subtype 1 on lymphocytes resulting in internalisation of the receptor and loss of responsiveness to the S1P gradient that drives lymphocyte egress from lymph nodes. The reduction in circulating lymphocytes presumably limits inflammatory cell migration into the CNS. Four S1PR modulators (fingolimod, siponimod, ozanimod, and ponesimod) have regulatory approval for multiple sclerosis. Preclinical evidence and ongoing and completed clinical trials support development of S1PR modulators for other therapeutic indications.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(21)00244-0</identifier><identifier>PMID: 34175020</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Alzheimer's disease ; Angiogenesis ; Animals ; Autoimmune diseases ; Azetidines - pharmacology ; Azetidines - therapeutic use ; Benzyl Compounds - pharmacology ; Benzyl Compounds - therapeutic use ; Clinical trials ; Clinical Trials as Topic ; Cytokines ; Egress ; Encephalomyelitis ; Fingolimod Hydrochloride - pharmacology ; Fingolimod Hydrochloride - therapeutic use ; Graft rejection ; Heart rate ; Humans ; Immune system ; Immune System Diseases - drug therapy ; Immunology ; Indans - pharmacology ; Indans - therapeutic use ; Inflammation ; Inflammatory diseases ; Kidney transplantation ; Leukocyte migration ; Lymph nodes ; Lymphatic system ; Lymphocytes ; Modulators ; Multiple sclerosis ; Multiple Sclerosis - drug therapy ; Nervous System Diseases - drug therapy ; Neurogenesis ; Oxadiazoles - pharmacology ; Oxadiazoles - therapeutic use ; Permeability ; Receptors ; Regulation ; Regulatory approval ; Signal transduction ; Signal Transduction - drug effects ; Smooth muscle ; Sphingosine 1 Phosphate Receptor Modulators - classification ; Sphingosine 1 Phosphate Receptor Modulators - pharmacology ; Sphingosine 1 Phosphate Receptor Modulators - therapeutic use ; Sphingosine 1-phosphate ; Sphingosine-1-Phosphate Receptors ; Thiazoles - pharmacology ; Thiazoles - therapeutic use ; Transplantation</subject><ispartof>The Lancet (British edition), 2021-09, Vol.398 (10306), p.1184-1194</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><rights>2021. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-abf38b0c4517c24430848577824beb012ba0f19acd861049eb20a66a4ef669b83</citedby><cites>FETCH-LOGICAL-c511t-abf38b0c4517c24430848577824beb012ba0f19acd861049eb20a66a4ef669b83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2575802451?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34175020$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McGinley, Marisa P</creatorcontrib><creatorcontrib>Cohen, Jeffrey A</creatorcontrib><title>Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>The sphingosine 1-phosphate (S1P) signalling pathways have important and diverse functions. S1P receptors (S1PRs) have been proposed as a therapeutic target for various diseases due to their involvement in regulation of lymphocyte trafficking, brain and cardiac function, vascular permeability, and vascular and bronchial tone. S1PR modulators were first developed to prevent rejection by the immune system following renal transplantation, but the only currently approved indication is multiple sclerosis. The primary mechanism of action of S1PR modulators in multiple sclerosis is through binding S1PR subtype 1 on lymphocytes resulting in internalisation of the receptor and loss of responsiveness to the S1P gradient that drives lymphocyte egress from lymph nodes. The reduction in circulating lymphocytes presumably limits inflammatory cell migration into the CNS. Four S1PR modulators (fingolimod, siponimod, ozanimod, and ponesimod) have regulatory approval for multiple sclerosis. Preclinical evidence and ongoing and completed clinical trials support development of S1PR modulators for other therapeutic indications.</description><subject>Alzheimer's disease</subject><subject>Angiogenesis</subject><subject>Animals</subject><subject>Autoimmune diseases</subject><subject>Azetidines - pharmacology</subject><subject>Azetidines - therapeutic use</subject><subject>Benzyl Compounds - pharmacology</subject><subject>Benzyl Compounds - therapeutic use</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Cytokines</subject><subject>Egress</subject><subject>Encephalomyelitis</subject><subject>Fingolimod Hydrochloride - pharmacology</subject><subject>Fingolimod Hydrochloride - therapeutic use</subject><subject>Graft rejection</subject><subject>Heart rate</subject><subject>Humans</subject><subject>Immune system</subject><subject>Immune System Diseases - drug therapy</subject><subject>Immunology</subject><subject>Indans - pharmacology</subject><subject>Indans - therapeutic use</subject><subject>Inflammation</subject><subject>Inflammatory diseases</subject><subject>Kidney transplantation</subject><subject>Leukocyte migration</subject><subject>Lymph nodes</subject><subject>Lymphatic system</subject><subject>Lymphocytes</subject><subject>Modulators</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Nervous System Diseases - drug therapy</subject><subject>Neurogenesis</subject><subject>Oxadiazoles - pharmacology</subject><subject>Oxadiazoles - therapeutic use</subject><subject>Permeability</subject><subject>Receptors</subject><subject>Regulation</subject><subject>Regulatory approval</subject><subject>Signal transduction</subject><subject>Signal Transduction - drug effects</subject><subject>Smooth muscle</subject><subject>Sphingosine 1 Phosphate Receptor Modulators - classification</subject><subject>Sphingosine 1 Phosphate Receptor Modulators - pharmacology</subject><subject>Sphingosine 1 Phosphate Receptor Modulators - therapeutic use</subject><subject>Sphingosine 1-phosphate</subject><subject>Sphingosine-1-Phosphate Receptors</subject><subject>Thiazoles - pharmacology</subject><subject>Thiazoles - therapeutic use</subject><subject>Transplantation</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkE1P3DAQhi3UChbKT6Cy1As9pIwd2_GeKoRaioTEAai4WY4zYY0SO7WTSv339bKUQy-cZg7POx8PIScMvjBg6uwWmIBKNbU65ewzABeigj2yYqIRlRTNwzuyekUOyGHOTwAgFMh9clAL1kjgsCI_b6eND48x-4CUVdMm5mljZ6QJHU5zTHSM3TLY0mXqAx2XYfbTgDS7AVOJZWpDR-O8wURdDJ2ffQz5A3nf2yHj8Us9Ivffv91d_Kiuby6vLs6vKycZmyvb9rVuwQnJGlc-qEELLZtGc9FiC4y3Fnq2tq7TioFYY8vBKmUF9kqtW10fkdPd3CnFXwvm2Yw-OxwGGzAu2XAp5ForzVlBP_2HPsUlhXJdoRqpi0G5peSOcuW5nLA3U_KjTX8MA7MVb57Fm61Vw5l5Fm-g5D6-TF_aEbvX1D_TBfi6A7Do-O0xmew8BoedL6pn00X_xoq_KKeSEw</recordid><startdate>20210925</startdate><enddate>20210925</enddate><creator>McGinley, Marisa P</creator><creator>Cohen, Jeffrey A</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20210925</creationdate><title>Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions</title><author>McGinley, Marisa P ; Cohen, Jeffrey A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-abf38b0c4517c24430848577824beb012ba0f19acd861049eb20a66a4ef669b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alzheimer's disease</topic><topic>Angiogenesis</topic><topic>Animals</topic><topic>Autoimmune diseases</topic><topic>Azetidines - pharmacology</topic><topic>Azetidines - therapeutic use</topic><topic>Benzyl Compounds - pharmacology</topic><topic>Benzyl Compounds - therapeutic use</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Cytokines</topic><topic>Egress</topic><topic>Encephalomyelitis</topic><topic>Fingolimod Hydrochloride - pharmacology</topic><topic>Fingolimod Hydrochloride - therapeutic use</topic><topic>Graft rejection</topic><topic>Heart rate</topic><topic>Humans</topic><topic>Immune system</topic><topic>Immune System Diseases - drug therapy</topic><topic>Immunology</topic><topic>Indans - pharmacology</topic><topic>Indans - therapeutic use</topic><topic>Inflammation</topic><topic>Inflammatory diseases</topic><topic>Kidney transplantation</topic><topic>Leukocyte migration</topic><topic>Lymph nodes</topic><topic>Lymphatic system</topic><topic>Lymphocytes</topic><topic>Modulators</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Nervous System Diseases - drug therapy</topic><topic>Neurogenesis</topic><topic>Oxadiazoles - pharmacology</topic><topic>Oxadiazoles - therapeutic use</topic><topic>Permeability</topic><topic>Receptors</topic><topic>Regulation</topic><topic>Regulatory approval</topic><topic>Signal transduction</topic><topic>Signal Transduction - drug effects</topic><topic>Smooth muscle</topic><topic>Sphingosine 1 Phosphate Receptor Modulators - classification</topic><topic>Sphingosine 1 Phosphate Receptor Modulators - pharmacology</topic><topic>Sphingosine 1 Phosphate Receptor Modulators - therapeutic use</topic><topic>Sphingosine 1-phosphate</topic><topic>Sphingosine-1-Phosphate Receptors</topic><topic>Thiazoles - pharmacology</topic><topic>Thiazoles - therapeutic use</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McGinley, Marisa P</creatorcontrib><creatorcontrib>Cohen, Jeffrey A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McGinley, Marisa P</au><au>Cohen, Jeffrey A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2021-09-25</date><risdate>2021</risdate><volume>398</volume><issue>10306</issue><spage>1184</spage><epage>1194</epage><pages>1184-1194</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><abstract>The sphingosine 1-phosphate (S1P) signalling pathways have important and diverse functions. S1P receptors (S1PRs) have been proposed as a therapeutic target for various diseases due to their involvement in regulation of lymphocyte trafficking, brain and cardiac function, vascular permeability, and vascular and bronchial tone. S1PR modulators were first developed to prevent rejection by the immune system following renal transplantation, but the only currently approved indication is multiple sclerosis. The primary mechanism of action of S1PR modulators in multiple sclerosis is through binding S1PR subtype 1 on lymphocytes resulting in internalisation of the receptor and loss of responsiveness to the S1P gradient that drives lymphocyte egress from lymph nodes. The reduction in circulating lymphocytes presumably limits inflammatory cell migration into the CNS. Four S1PR modulators (fingolimod, siponimod, ozanimod, and ponesimod) have regulatory approval for multiple sclerosis. Preclinical evidence and ongoing and completed clinical trials support development of S1PR modulators for other therapeutic indications.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>34175020</pmid><doi>10.1016/S0140-6736(21)00244-0</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2021-09, Vol.398 (10306), p.1184-1194 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2545986821 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Alzheimer's disease Angiogenesis Animals Autoimmune diseases Azetidines - pharmacology Azetidines - therapeutic use Benzyl Compounds - pharmacology Benzyl Compounds - therapeutic use Clinical trials Clinical Trials as Topic Cytokines Egress Encephalomyelitis Fingolimod Hydrochloride - pharmacology Fingolimod Hydrochloride - therapeutic use Graft rejection Heart rate Humans Immune system Immune System Diseases - drug therapy Immunology Indans - pharmacology Indans - therapeutic use Inflammation Inflammatory diseases Kidney transplantation Leukocyte migration Lymph nodes Lymphatic system Lymphocytes Modulators Multiple sclerosis Multiple Sclerosis - drug therapy Nervous System Diseases - drug therapy Neurogenesis Oxadiazoles - pharmacology Oxadiazoles - therapeutic use Permeability Receptors Regulation Regulatory approval Signal transduction Signal Transduction - drug effects Smooth muscle Sphingosine 1 Phosphate Receptor Modulators - classification Sphingosine 1 Phosphate Receptor Modulators - pharmacology Sphingosine 1 Phosphate Receptor Modulators - therapeutic use Sphingosine 1-phosphate Sphingosine-1-Phosphate Receptors Thiazoles - pharmacology Thiazoles - therapeutic use Transplantation |
| title | Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T02%3A22%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sphingosine%201-phosphate%20receptor%20modulators%20in%20multiple%20sclerosis%20and%20other%20conditions&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=McGinley,%20Marisa%20P&rft.date=2021-09-25&rft.volume=398&rft.issue=10306&rft.spage=1184&rft.epage=1194&rft.pages=1184-1194&rft.issn=0140-6736&rft.eissn=1474-547X&rft_id=info:doi/10.1016/S0140-6736(21)00244-0&rft_dat=%3Cproquest_cross%3E2545986821%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2575802451&rft_id=info:pmid/34175020&rft_els_id=S0140673621002440&rfr_iscdi=true |